{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:19:08Z","timestamp":1785323948568,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03245-0","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T03:56:52Z","timestamp":1750651012000},"page":"4318-4334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology and Steroid Dependency Reduction in Crohn\u2019s Disease During the Biologics Era: A Nationwide Population-Based Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Nai-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Hsiung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yea-Huei","family":"Kao Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9258-3239","authenticated-orcid":false,"given":"Ching-Lan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"3","key":"3245_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065186","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023;13(3): e065186. https:\/\/doi.org\/10.1136\/bmjopen-2022-065186.","journal-title":"BMJ Open"},{"issue":"1","key":"3245_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, et al. ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14(1):4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis"},{"key":"3245_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/jir.s165330","volume":"11","author":"P Rawla","year":"2018","unstructured":"Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives (in Eng). J Inflamm Res. 2018;11:215\u201326. https:\/\/doi.org\/10.2147\/jir.s165330.","journal-title":"J Inflamm Res"},{"issue":"7","key":"3245_CR4","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","volume":"70","author":"GR D\u2019Haens","year":"2021","unstructured":"D\u2019Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. 2021;70(7):1396\u2013405. https:\/\/doi.org\/10.1136\/gutjnl-2019-320022.","journal-title":"Gut"},{"issue":"9","key":"3245_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrgastro.2015.135","volume":"12","author":"S Danese","year":"2015","unstructured":"Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12(9):537\u201345. https:\/\/doi.org\/10.1038\/nrgastro.2015.135.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"14","key":"3245_CR6","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMra1907607","volume":"385","author":"DC Baumgart","year":"2021","unstructured":"Baumgart DC, Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N Engl J Med. 2021;385(14):1302\u201315. https:\/\/doi.org\/10.1056\/NEJMra1907607.","journal-title":"N Engl J Med"},{"issue":"1","key":"3245_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, et al. ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2\u201317. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab178.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"3245_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5217\/ir.2017.15.3.266","volume":"15","author":"SC Wei","year":"2017","unstructured":"Wei SC, et al. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of inflammatory bowel disease. Intest Res. 2017;15(3):266\u201384. https:\/\/doi.org\/10.5217\/ir.2017.15.3.266.","journal-title":"Intest Res"},{"issue":"3","key":"3245_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5217\/ir.2017.15.3.285","volume":"15","author":"SC Wei","year":"2017","unstructured":"Wei SC, et al. Management of Crohn\u2019s disease in Taiwan: consensus guideline of the Taiwan Society of inflammatory bowel disease. Intest Res. 2017;15(3):285\u2013310. https:\/\/doi.org\/10.5217\/ir.2017.15.3.285.","journal-title":"Intest Res"},{"issue":"5","key":"3245_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, et al. STRIDE-II: an Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"issue":"9","key":"3245_CR11","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.clinthera.2018.07.013","volume":"40","author":"JE Brady","year":"2018","unstructured":"Brady JE, Stott-Miller M, Mu G, Perera S. Treatment patterns and sequencing in patients with inflammatory bowel disease. Clin Ther. 2018;40(9):1509\u201321. https:\/\/doi.org\/10.1016\/j.clinthera.2018.07.013.","journal-title":"Clin Ther"},{"issue":"3","key":"3245_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/00365521.2020.1726445","volume":"55","author":"S Alulis","year":"2020","unstructured":"Alulis S, et al. Treatment patterns for biologics in ulcerative colitis and Crohn\u2019s disease: a Danish Nationwide Register Study from 2003 to 2015. Scand J Gastroenterol. 2020;55(3):265\u201371. https:\/\/doi.org\/10.1080\/00365521.2020.1726445.","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"3245_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/apt.13700","volume":"44","author":"V Chhaya","year":"2016","unstructured":"Chhaya V, et al. Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study. Aliment Pharmacol Ther. 2016;44(5):482\u201394. https:\/\/doi.org\/10.1111\/apt.13700.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3245_CR14","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3904\/kjim.2020.001","volume":"35","author":"YS Jung","year":"2020","unstructured":"Jung YS, Han M, Park S, Cheon JH. Impact of early anti-TNF use on clinical outcomes in Crohn\u2019s disease: a Nationwide population-based study. Korean J Intern Med. 2020;35(5):1104\u201313. https:\/\/doi.org\/10.3904\/kjim.2020.001.","journal-title":"Korean J Intern Med"},{"key":"3245_CR15","unstructured":"T. S. N. H. I. Administration, \"Chapter 8.\" [Online]. Available: https:\/\/www.nhi.gov.tw\/DL.aspx?sitessn=292&u=LzAwMS9VcGxvYWQvMjkyL3JlbGZpbGUvMC82MTM2L2NoYXA4XzExMTA1LnBkZg%3d%3d&n=Y2hhcDhfMTExMDUucGRm&ico%20=.pdf."},{"issue":"6","key":"3245_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158017","volume":"11","author":"AK Waljee","year":"2016","unstructured":"Waljee AK, et al. Corticosteroid use and complications in a US inflammatory bowel disease Cohort. PLoS One. 2016;11(6): e0158017. https:\/\/doi.org\/10.1371\/journal.pone.0158017.","journal-title":"PLoS One"},{"key":"3245_CR17","unstructured":"TSNHI Administration, \u201cPatients with Catastrophic Illnesses or Rare Diseases.\u201d [Online]. Available: https:\/\/www.nhi.gov.tw\/english\/Content_List.aspx?n=F5B8E49CB4548C60&topn=1D1ECC54F86E9050."},{"key":"3245_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, et al. Taiwan\u2019s National Health Insurance research database: past and future. Clin Epidemiol. 2019;11:349\u201358. https:\/\/doi.org\/10.2147\/CLEP.S196293.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"3245_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5217\/ir.2018.00096","volume":"17","author":"HH Yen","year":"2019","unstructured":"Yen HH, et al. Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study. Intest Res. 2019;17(1):54\u201362. https:\/\/doi.org\/10.5217\/ir.2018.00096.","journal-title":"Intest Res"},{"key":"3245_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-230x-13-166","volume":"13","author":"SC Wei","year":"2013","unstructured":"Wei SC, et al. A Nationwide population-based study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan (in Eng). BMC Gastroenterol. 2013;13:166. https:\/\/doi.org\/10.1186\/1471-230x-13-166.","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"3245_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5217\/ir.2021.00115","volume":"20","author":"SH Park","year":"2002","unstructured":"Park SH. Update on the epidemiology of inflammatory bowel disease in Asia: where are we now? Intest Res. 2002;20(2):159\u201364. https:\/\/doi.org\/10.5217\/ir.2021.00115.","journal-title":"Intest Res"},{"key":"3245_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz148","author":"ED Elias","year":"2019","unstructured":"Elias ED, Targownik LE, Singh H, Bernstein CN. A population-based study of combination vs monotherapy of anti-TNF in persons with IBD (in Eng). Inflamm Bowel Dis. 2019. https:\/\/doi.org\/10.1093\/ibd\/izz148.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"3245_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/ibd\/izx065","volume":"24","author":"S Bots","year":"2018","unstructured":"Bots S, Gecse K, Barclay M, D\u2019Haens G. Combination immunosuppression in IBD (in Eng). Inflamm Bowel Dis. 2018;24(3):539\u201345. https:\/\/doi.org\/10.1093\/ibd\/izx065.","journal-title":"Inflamm Bowel Dis"},{"key":"3245_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3003","author":"NY Chen","year":"2023","unstructured":"Chen NY, Chuang CH, Chang YC, Yang YK, Chen PH, Cheng CL. Suboptimal outcomes and retreatment rate of Crohn\u2019s disease patients after forced discontinuation of biologics: a Nationwide Population-Based Study (in Eng). Clin Pharmacol Ther. 2023. https:\/\/doi.org\/10.1002\/cpt.3003.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"3245_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase H, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489\u2013526. https:\/\/doi.org\/10.1007\/s00535-021-01784-1.","journal-title":"J Gastroenterol"},{"issue":"1","key":"3245_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00535-012-0673-1","volume":"48","author":"F Ueno","year":"2013","unstructured":"Ueno F, et al. Evidence-based clinical practice guidelines for Crohn\u2019s disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013;48(1):31\u201372. https:\/\/doi.org\/10.1007\/s00535-012-0673-1.","journal-title":"J Gastroenterol"},{"key":"3245_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008870.pub2","author":"WC Lim","year":"2016","unstructured":"Lim WC, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn\u2019s disease. Cochrane Database Syst Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.CD008870.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"3245_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008414.pub3","author":"T Gjuladin-Hellon","year":"2019","unstructured":"Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn\u2019s disease (in Eng). Cochrane Database Syst Rev. 2019. https:\/\/doi.org\/10.1002\/14651858.CD008414.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"30","key":"3245_CR29","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.3748\/wjg.v28.i30.4102","volume":"28","author":"LY Yao","year":"2022","unstructured":"Yao LY, et al. Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease (in Eng). World J Gastroenterol. 2022;28(30):4102\u201319. https:\/\/doi.org\/10.3748\/wjg.v28.i30.4102.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3245_CR30","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s12325-020-01615-4","volume":"38","author":"C Miyazaki","year":"2021","unstructured":"Miyazaki C, Sakashita T, Jung W, Kato S. Real-world prescription pattern and healthcare cost among patients with ulcerative Colitis in Japan: a retrospective claims data analysis. Adv Ther. 2021;38(5):2229\u201347. https:\/\/doi.org\/10.1007\/s12325-020-01615-4.","journal-title":"Adv Ther"},{"issue":"10","key":"3245_CR31","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, et al. ECCO Guidelines on therapeutics in Crohn\u2019s disease: medical treatment (in Eng). J Crohns Colitis. 2024;18(10):1531\u201355. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae091.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"3245_CR32","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and Perianal Fistulizing Crohn\u2019s Disease (in Eng). Gastroenterology. 2021;160(7):2496\u2013508. https:\/\/doi.org\/10.1053\/j.gastro.2021.04.022.","journal-title":"Gastroenterology"},{"issue":"8","key":"3245_CR33","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/ibd\/izaa263","volume":"27","author":"G Chen","year":"2021","unstructured":"Chen G, Lissoos T, Dieyi C, Null KD. Development and validation of an inflammatory bowel disease severity index using US administrative claims data: a retrospective Cohort Study (in Eng). Inflamm Bowel Dis. 2021;27(8):1177\u201383. https:\/\/doi.org\/10.1093\/ibd\/izaa263.","journal-title":"Inflamm Bowel Dis"},{"key":"3245_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/0046958019887816","author":"Y Ye","year":"2019","unstructured":"Ye Y, Manne S, Bennett D. Identifying patients with inflammatory bowel diseases in an administrative health claims database: do algorithms generate similar findings? (in Eng). Inquiry. 2019. https:\/\/doi.org\/10.1177\/0046958019887816.","journal-title":"Inquiry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03245-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03245-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:04:11Z","timestamp":1756371851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03245-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3245"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03245-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nai-Yu Chen, Chiao-Hsiung Chuang, Yu-Ching Chang, Yea-Huei Kao Yang, and Ching-Lan Cheng disclose no relevant financial or personal relationships that could be perceived as a competing interest related to this work. Hua Hsu and Chieh-Min Chen are affiliated with Takeda Pharmaceuticals Taiwan, Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Institutional Review Board of National Cheng Kung University Hospital (approval number A-EX-108\u2013049; the informed consent requirement was waived). All collaborating institutions involved in this study also received ethical approval from their respective ethics committees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}